NovaBay Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds which it has named Aganocide compounds which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections including Methicillin-Resistant Staphylococcus aureus. Novabay Pharmaceuticals Inc. has a market cap of $40.5 million; its shares were traded at around $1.85 with and P/S ratio of 6.
Recent Trades of NovaBay Pharmaceuticals Inc. by Directors and Officers:
- Buy: Director Harry F Jr Hixson bought 25,000 shares of NBY stock on 06/11/2009 at the average price of $2.33; the price of the stock has decreased by 20.6% since.
- Sell: Director Paul E. Freiman sold 25,000 shares of NBY stock on 06/11/2009 at the average price of $2.33; the price of the stock has decreased by 20.6% since.